tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MedAdvisor Faces ASX Suspension Over Delayed Financial Report

Story Highlights
MedAdvisor Faces ASX Suspension Over Delayed Financial Report

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

MedAdvisor Limited ( (AU:MDR) ) has provided an announcement.

MedAdvisor Limited announced that its securities have been suspended from quotation on the ASX due to the company’s failure to submit its FY25 Financial Report by the deadline. The company plans to lodge the audited report during the week starting 6 October 2025. This suspension could impact the company’s market perception and stakeholder confidence, highlighting the importance of timely financial reporting.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

More about MedAdvisor Limited

MedAdvisor Solutions is a leader in pharmacy-driven patient engagement solutions, offering personalized experiences to simplify the medication journey. Utilizing THRiV, a cloud-based, AI-enabled platform, the company enhances pharmacy workflows and patient engagement, working with over 34,000 pharmacies across the US, reaching over two-thirds of the population.

Average Trading Volume: 939,764

Technical Sentiment Signal: Sell

Current Market Cap: A$26.56M

For an in-depth examination of MDR stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1